These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 29992802)

  • 21. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
    Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
    Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach.
    Augurzky B; Göhlmann S; Gress S; Wasem J
    Health Econ; 2009 Apr; 18(4):421-36. PubMed ID: 18677725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sharing, samples, and generics: an antitrust framework.
    Carrier MA
    Cornell Law Rev; 2017; 103(1):1-64. PubMed ID: 29236427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the Impact of Food and Drug Administration's Unapproved Drug Initiative on Drug Prices and Sales.
    Sharma D; Schumock GT; Saffore CD; Albert Edwards S; Walton SM
    Ther Innov Regul Sci; 2020 Mar; 54(2):424-430. PubMed ID: 32072591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limited distribution networks stifle competition in the generic and biosimilar drug industries.
    Karas L; Shermock KM; Proctor C; Socal M; Anderson GF
    Am J Manag Care; 2018 Apr; 24(4):e122-e127. PubMed ID: 29668215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation.
    Chaloupka FJ; Warner KE; Acemoğlu D; Gruber J; Laux F; Max W; Newhouse J; Schelling T; Sindelar J
    Tob Control; 2015 Mar; 24(2):112-9. PubMed ID: 25550419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of Market Exclusivity for Prescription Drugs in the United States.
    Kesselheim AS; Sinha MS; Avorn J
    JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
    Kelly JJ; David M
    Food Drug Law J; 2009; 64(1):115-48. PubMed ID: 19998743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.
    Gupta R; Dhruva SS; Fox ER; Ross JS
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1066-1076. PubMed ID: 28944731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Competition and prices in the Mexican pharmaceutical market].
    Molina-Salazar RE; González-Marín E; Carbajal-de Nova C
    Salud Publica Mex; 2008; 50 Suppl 4():S496-503. PubMed ID: 19082261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategies That Delay Market Entry of Generic Drugs.
    Vokinger KN; Kesselheim AS; Avorn J; Sarpatwari A
    JAMA Intern Med; 2017 Nov; 177(11):1665-1669. PubMed ID: 28975217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic Drugs, Biosimilars, and Barriers to Entry.
    Shepherd JM
    Health Matrix Clevel; 2015; 25():139-61. PubMed ID: 29485844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
    Karnon J; Edney L; Sorich M
    Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Incomplete Prescription: President Trump's Plan to Address High Drug Prices.
    Sarpatwari A; Avorn J; Kesselheim AS
    JAMA; 2018 Jun; 319(23):2373-2374. PubMed ID: 29800027
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
    Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
    Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Projecting future drug expenditures--1993.
    Santell JP
    Am J Hosp Pharm; 1993 Jan; 50(1):71-7. PubMed ID: 8427283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promoting Competition in Drug Pricing: A Review of Recent Congressional Legislation.
    Nagar S; Kesselheim AS
    J Law Med Ethics; 2021; 49(4):683-687. PubMed ID: 35006061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.